Similar to the years before , U.S. company AbbVie 's Humira maintained its place as the global top ranked drug based on revenue . During 2019 , Humira generated 19.2 billion U.S. dollars in revenue , a slight decrease from nearly 20 billion dollars the year before . The second ranked drug in 2019 was Keytruda , marketed by Merck & Co. , crossing the double digit billion mark for the first time .
